US IPO Weekly Recap: CRISPR biotech pops 44% as more names join the IPO pipeline

LongbridgeAII'm LongbridgeAI. Here is the key information I extracted

One IPO priced this past week, joined by four SPACs.

Cardiovascular disease biotech Scribe Therapeutics (SCTX) upsized and priced at the high end to raise $129 million at a $273 million market cap. Scribe is developing in vivo CRISPR-based therapies, with an initial focus on cardiovascular and metabolic disease. Its lead candidate uses an epigenetic silencing approach to durably lower LDL-C by repressing PCSK9 expression, without permanently altering DNA. It's currently in a first-in-human trial in Australia under TGA clearance, with initial data expected in the first half of 2027. Scribe popped 44%.

Two sizable issuers joined the IPO pipeline, led by defense tech firm Lyntris (LYNX), which filed for an estimated $300 million offering.

7 Filings During the Week of July 20th, 2026
Issuer
Business
Deal
Size
SectorLead
Underwriter
Bluerock Acquisition II (BRRKU)$150MSPACBTIG
Blank check company backed by Bluerock targeting Web3 businesses.
K2 Capital Acquisition II (KIIU)$150MSPACD. Boral Capital
Blank check company targeting national defense and critical infrastructure.
Lyntris (LYNX)$300MIndustrialsEvercore ISI
Provides defense tech connectivity solutions for military operations.
NorthStrive Acquisition I (NOSU.RC)$100MSPACD. Boral Capital
Blank check company targeting manufacturing companies.
Pinnacle Acquisition (PNAQ.U)$200MSPACSantander
Blank check company targeting commercial and consumer finance businesses.
Gravitics (GVTX)$125MIndustrialsLucid Cap. Mkts.
Develops large space structures and orbital systems.
TCGX Acquisition (TCGX)$75MSPACJefferies
Blank check company formed by TCGX executives targeting healthcare in Asia.

IPO Market Snapshot
The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 7/23/2026, the Renaissance IPO Index was up 16.7% year-to-date, while the S&P 500 was up 8.9%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Astera Labs (ALAB) and CoreWeave (CRWV). The Renaissance International IPO Index was up 38.7% year-to-date, while the ACWX was up 12.9%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Galderma and CATL.

Source: RenaissanceCapital The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.